Committing To Drug Development In World's Biggest Market: SK's Story
South Korean companies are seeking diverse ways to enter global drug markets, and SK Biopharmaceuticals is leading the way by establishing physical R&D and commercial operations in the US to progress its CNS drug pipeline. Executives of SK Life Science, the US subsidiary of SK Biopharmaceuticals, talk to Scrip about why they are committed to developing drugs in the US and what advantages and challenges they have by establishing a footprint in this key market.
You may also be interested in...
SK Biopharmaceuticals vice-president Haein Shin talks to Scrip about the company’s long journey to developing and launching novel innovative CNS drugs in global markets and what is behind its achievement, which is seen as unprecedented in the South Korean pharma industry.
SK Biopharmaceuticals receives US approval for novel anti-epileptic drug, marking a major milestone for the South Korean firm in its goal of becoming a fully integrated global pharma and potentially boosting its huge planned IPO. Through its US subsidiary, the SK Group company will independently market and sell the product in the world’s biggest single market.
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.